Bruker (BRKR) financial statements
Bruker reported revenue of $3.4B in fiscal 2025, up 8.8% a year over 9 years.
Net income was -$9M and the operating margin 2.0%, against 11.3% in 2016.
Free cash flow was $43M, and the company returned $23M in dividends and $10M in net buybacks.
The diluted share count fell 6% over the period (buybacks).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Bruker's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.6B | $1.8B | $1.9B | $2.1B | $2.0B | $2.4B | $2.5B | $3.0B | $3.4B | $3.4B |
| Cost of revenue | $866M | $950M | $996M | $1.1B | $1.0B | $1.2B | $1.2B | $1.5B | $1.7B | $1.9B |
| Gross profit | $745M | $816M | $900M | $995M | $940M | $1.2B | $1.3B | $1.5B | $1.6B | $1.6B |
| Research and development | $148M | $162M | $173M | $188M | $198M | $221M | $236M | $295M | $376M | $395M |
| Selling, general and admin | $390M | $415M | $445M | $500M | $469M | $561M | $607M | $729M | $894M | $946M |
| Operating income | $182M | $220M | $262M | $301M | $248M | $413M | $433M | $437M | $253M | $68M |
| Interest expense | $13M | $15M | $13M | $16M | $14M | $14M | $16M | $16M | $48M | $60M |
| Pre-tax income | $178M | $198M | $245M | $280M | $226M | $394M | $414M | $544M | $207M | $22M |
| Income tax | $23M | $118M | $64M | $82M | $64M | $113M | $116M | $118M | $91M | $29M |
| Net income | $154M | $79M | $180M | $197M | $158M | $277M | $297M | $427M | $113M | -$9M |
| EPS (diluted) | $0.95 | $0.49 | $1.14 | $1.26 | $1.02 | $1.81 | $1.99 | $2.90 | $0.76 | -$0.15 |
| Diluted shares | 162M | 159M | 157M | 157M | 155M | 153M | 149M | 147M | 150M | 152M |
| Gross margin | 46.3% | 46.2% | 47.5% | 48.0% | 47.3% | 50.0% | 51.6% | 51.0% | 49.0% | 45.9% |
| Operating margin | 11.3% | 12.4% | 13.8% | 14.5% | 12.5% | 17.1% | 17.1% | 14.7% | 7.5% | 2.0% |
| Net margin | 9.5% | 4.5% | 9.5% | 9.5% | 7.9% | 11.5% | 11.7% | 14.4% | 3.4% | -0.3% |
Balance sheet
Fiscal years, from Bruker's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $500M | $439M | $322M | $685M | $732M | $1.2B | $646M | $488M | $183M | $299M |
| Receivables | $244M | $319M | $357M | $362M | $335M | $417M | $473M | $492M | $566M | $545M |
| Inventory | $440M | $486M | $510M | $577M | $692M | $710M | $800M | $968M | $1.1B | $1.1B |
| Total current assets | $1.3B | $1.4B | $1.3B | $1.8B | $1.9B | $2.5B | $2.1B | $2.2B | $2.1B | $2.2B |
| Property, plant and equipment | $239M | $266M | $271M | $306M | $396M | $406M | $487M | $600M | $669M | $745M |
| Goodwill | $131M | $170M | $276M | $293M | $320M | $340M | $458M | $583M | $1.5B | $1.5B |
| Total assets | $1.8B | $1.9B | $2.1B | $2.8B | $3.0B | $3.6B | $3.6B | $4.2B | $5.8B | $6.2B |
| Total current liabilities | $525M | $524M | $599M | $646M | $792M | $938M | $914M | $1.2B | $1.3B | $1.3B |
| Long-term debt | $392M | $416M | $323M | $813M | $842M | $1.2B | $1.2B | $1.2B | $2.1B | $1.9B |
| Total liabilities | $1.1B | $1.2B | $1.2B | $1.9B | $2.1B | $2.6B | $2.5B | $2.8B | $4.0B | $3.7B |
| Shareholders' equity | $686M | $725M | $897M | $907M | $961M | $1.1B | $1.1B | $1.4B | $1.8B | $2.5B |
| Net debt | $49M | $91M | $200,000 | $134M | $160M | $154M | $555M | $672M | $1.9B | $1.6B |
Cash flow
Fiscal years, from Bruker's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $131M | $154M | $240M | $213M | $332M | $282M | $274M | $350M | $251M | $134M |
| Capital spending | $37M | $44M | $49M | $73M | $97M | $92M | $129M | $107M | $115M | $91M |
| Free cash flow | $94M | $111M | $190M | $140M | $235M | $190M | $145M | $243M | $136M | $43M |
| Stock-based compensation | $9M | $11M | $11M | $10M | $16M | $17M | $28M | $31M | $25M | $20M |
| Dividends paid | $26M | $25M | $25M | $25M | $25M | $24M | $30M | $29M | $30M | $23M |
| Share buybacks (net) | -$160M | -$152M | — | -$142M | -$123M | -$153M | -$263M | -$152M | $0 | -$10M |
| Net borrowing | -$100,000 | — | — | $583M | $0 | $492M | -$111M | -$22M | $838M | -$463M |
| Free cash flow margin | 5.8% | 6.3% | 10.0% | 6.8% | 11.8% | 7.9% | 5.7% | 8.2% | 4.0% | 1.3% |
| Dividends per share | $0.16 | $0.16 | $0.16 | $0.16 | $0.16 | $0.16 | $0.20 | $0.20 | $0.20 | $0.15 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BRKR.
Open BRKR in InvestinglyQuestions
What was Bruker's revenue in 2025?
$3.4B in fiscal 2025, from its 10-K filing.
How much free cash flow does Bruker generate?
$43M in fiscal 2025 (operating cash flow minus capital spending).
From Bruker's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.